NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: A genotype-based meta-analysis

NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: A genotype-based meta-analysis

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. Background NAT2 slow acetylator is a confirmed risk of anti-tuberculosis drug-induced liver injury (ATDILI). However, NAT2 ultra-slow acetylators, a new refinement among NAT2 slow acetylators, have been recently proposed. The patients...

Full description

Saved in:
Bibliographic Details
Main Authors: Supharat Suvichapanich, Koya Fukunaga, Hilyatuz Zahroh, Taisei Mushiroda, Surakameth Mahasirimongkol, Licht Toyo-Oka, Usa Chaikledkaew, Jiraphun Jittikoon, Rika Yuliwulandari, Hideki Yanai, Sukanya Wattanapokayakit, Katsushi Tokunaga
Other Authors: Japan Anti-Tuberculosis Association
Format: Article
Published: 2019
Subjects:
Biochemistry, Genetics and Molecular Biology
Medicine
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/45338
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University

Internet

https://repository.li.mahidol.ac.th/handle/123456789/45338

Similar Items